Kyverna Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Kyverna Therapeutics, Inc. (KYTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.51M, a 39.28% increase year-over-year.
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.17M, a 46.74% increase year-over-year.
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.70M, a 20.92% decline year-over-year.
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.52M, a 96.11% increase year-over-year.
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.08M, a 20.62% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.36M, a 276.44% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.22M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51M 10-Q · filed 2026-08-11 | $6.68M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $3.17M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $10.08M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $2.70M 10-Q · filed 2025-11-12 | $5.22M derived: sum of 2 quarters · filed 2026-08-11 | $7.38M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $2.52M 10-Q · filed 2026-08-11 | $4.68M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.16M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $8.36M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $3.41M 10-Q · filed 2025-11-12 | $4.70M derived: sum of 2 quarters · filed 2025-11-12 | $6.97M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.28M 10-Q · filed 2025-11-12 | $3.56M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $2.28M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $2.22M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $521.00K 10-Q · filed 2024-11-13 | $968.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.44M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $447.00K 10-Q · filed 2024-11-13 | $915.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $468.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |